Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
VTGN Stock Chart & Stats
$3.99
-$0.08(-2.56%)
At close: 4:00 PM EST
$3.99
-$0.08(-2.56%)
Day’s Range― - ―
52-Week Range$1.90 - $4.65
Previous CloseN/A
Volume188.19K
Average Volume (3M)510.91K
Market Cap
$128.24M
Enterprise ValueN/A
Total Cash (Recent Filing)$63.18M
Total Debt (Recent Filing)$2.36M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Feb 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding30,680,471
10 Day Avg. Volume469,689
30 Day Avg. Volume510,910
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)1.09
Price to Sales (P/S)157.98
P/FCF Ratio-1.82
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$15.50Price Target Upside288.47% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical TrialsVistaGen announced the completion of its Phase 3 PALISADE-3 study evaluating fasedienol for the acute treatment of social anxiety disorder, with topline results expected by YE25.
Financial PositionWith $63.2 million in cash as of June 30, 2025, the company is fully funded through readouts of both PALISADE trials and into an NDA submission expected in the first half of 2026.
Market PotentialPALISADE-3 and -4 represent dual shots on goal for confirmatory data to back positive results from PALISADE-2 to reach the potential >30 million patient market in the U.S. alone with a novel inhaled neurosteroid that avoids material systemic exposure and adverse events.
Bears Say
Clinical Trial FailuresAFFIRM-1 study of BNC210 in patients with social anxiety disorder had failed to meet both primary and all secondary endpoints.
VistaGen Therapeutics News
VTGN FAQ
What was VistaGen Therapeutics’s price range in the past 12 months?
VistaGen Therapeutics lowest stock price was $1.90 and its highest was $4.65 in the past 12 months.
What is VistaGen Therapeutics’s market cap?
VistaGen Therapeutics’s market cap is $128.24M.
When is VistaGen Therapeutics’s upcoming earnings report date?
VistaGen Therapeutics’s upcoming earnings report date is Feb 12, 2026 which is in 96 days.
How were VistaGen Therapeutics’s earnings last quarter?
Currently, no data Available
Is VistaGen Therapeutics overvalued?
According to Wall Street analysts VistaGen Therapeutics’s price is currently Undervalued.
Does VistaGen Therapeutics pay dividends?
VistaGen Therapeutics does not currently pay dividends.
What is VistaGen Therapeutics’s EPS estimate?
VistaGen Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does VistaGen Therapeutics have?
VistaGen Therapeutics has 30,680,471 shares outstanding.
What happened to VistaGen Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of VistaGen Therapeutics?
Currently, no hedge funds are holding shares in VTGN
VistaGen Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.50 (288.47% Upside)
$15.50 (288.47% Upside)
Blogger Sentiment
Bullish
VTGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▲ 218.9%
Last 30 Days ▲ 223.3%
Last 30 Days ▲ 223.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
29.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-39.30%
Trailing 12-Months
Company Description
VistaGen Therapeutics
VistaGen Therapeutics (VTGN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat central nervous system (CNS) disorders, with a primary emphasis on anxiety, depression, and other related conditions. The company utilizes its proprietary drug development platforms, including its stem cell technology, to create and advance new treatments that address significant unmet medical needs. VistaGen's core products include AV-101, an oral candidate for the treatment of major depressive disorder, and PH94B, a novel intranasal formulation for social anxiety disorder.
VTGN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in Vistagen's clinical programs and financial stability, despite increased R&D expenses and net loss. The company's progress in clinical trials and pipeline expansion is promising, although there are operational challenges such as the termination of a trial site.View all VTGN earnings summariesVTGN Stock 12 Month Forecast
Average Price Target
$15.50
▲(288.47% Upside)
Technical Analysis
MacroGenics
―
Ovid Therapeutics
―
Spero Therapeutics
―
Inhibikase Therapeutics
―
Surrozen
―
Ownership Overview
0.46% Insiders
6.59% Mutual Funds
37.25% Other Institutional Investors
49.75% Public Companies and Individual Investors